Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junbo Ge

Showing results (1121-1130 of 1,174) with videos related to

Pageof 118
Sort By:
JACC. Cardiovascular Interventions|September 10, 2021
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent ImplantationRoxana Mehran, Davide Cao, Dominick J Angiolillo, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 29, 2024
2024 Statement from Asia expert operators on transcatheter pulmonary valve replacementWenzhi Pan, Daxin Zhou, Ziyad M Hijazi, et al.
JAMA|March 16, 2015
Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trialYong Huo, Jianping Li, Xianhui Qin, et al.
Eclinicalmedicine|May 17, 2024
Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trialJie Wang, Yuehui Yin, Chengzhi Lu, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
JACC. Cardiovascular Interventions|August 20, 2021
Physiological Distribution and Local Severity of Coronary Artery Disease and Outcomes After Percutaneous Coronary InterventionDoosup Shin, Neng Dai, Seung Hun Lee, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Journal of the American College of Cardiology|November 19, 2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCIMarco Valgimigli, Davide Cao, Dominick J Angiolillo, et al.
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 22, 2024
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromesDavide Cao, Pascal Vranckx, Marco Valgimigli, et al.
Pageof 118

Showing results (1121-1130 of 1,174) with videos related to

Sort By:
Pageof 118
JACC. Cardiovascular Interventions|September 10, 2021
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent ImplantationRoxana Mehran, Davide Cao, Dominick J Angiolillo, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 29, 2024
2024 Statement from Asia expert operators on transcatheter pulmonary valve replacementWenzhi Pan, Daxin Zhou, Ziyad M Hijazi, et al.
JAMA|March 16, 2015
Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trialYong Huo, Jianping Li, Xianhui Qin, et al.
Eclinicalmedicine|May 17, 2024
Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trialJie Wang, Yuehui Yin, Chengzhi Lu, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
JACC. Cardiovascular Interventions|August 20, 2021
Physiological Distribution and Local Severity of Coronary Artery Disease and Outcomes After Percutaneous Coronary InterventionDoosup Shin, Neng Dai, Seung Hun Lee, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Journal of the American College of Cardiology|November 19, 2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCIMarco Valgimigli, Davide Cao, Dominick J Angiolillo, et al.
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 22, 2024
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromesDavide Cao, Pascal Vranckx, Marco Valgimigli, et al.
Pageof 118